(DOC) НББОУС 2 Бараа материал | Od OD
We assessed the efficacy and safety of the combination of the nucleotide polymerase inhibitor sofosbuvir, the NS5A inhibitor velpatasvir, and the NS3/4A protease inhibitor GS-9857 in patients with hepatitis C virus (HCV) genotype 1 infection. We performed an open-label trial at 32 sites in the United States and 2 sites in New Zealand of 197 ...